Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPC Satraplatin Prostate Cancer Rolling NDA To Complete In Second Half Of 2006

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm seeks second-line indication for the oral platinum compound following completion of accrual in pivotal SPARC trial.

You may also be interested in...



GPC Aims To Complete Satraplatin NDA In January, Despite Arbitration With Licensor Spectrum

Spectrum is seeking $12 million GPC was paid by sublicensee Pharmion.

GPC Aims To Complete Satraplatin NDA In January, Despite Arbitration With Licensor Spectrum

Spectrum is seeking $12 million GPC was paid by sublicensee Pharmion.

Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition

Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel